logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Pembrolizumab with or without standard adjuvant therapy after resection for nonsmall-cell lung cancer – adjuvant

< Back

Pembrolizumab with or without standard adjuvant therapy after resection for nonsmall-cell lung cancer – adjuvant

Drugs

Cancer and Palliative Care

December 2020


Adjuvant pembrolizumab with or without standard adjuvant treatment is in clinical development for the treatment of early-stage operable non-small cell lung cancer (NSCLC) after resection. NSCLC is the most common type of lung cancer. Early-stage lung cancer is typically treated with surgery to remove either part of or the whole of the lung, with adjuvant (additional treatment given after the primary treatment) chemotherapy and/or radiotherapy. Treatment with immunotherapy after surgery may provide better long-term survival prospects for patients with early-stage operable NSCLC.

Pembrolizumab is an immunotherapy drug administered by intravenous infusion. It works by improving the activity of white blood cells (T-cells) by blocking a protein, PD-L1, thereby increasing the ability of the immune system to kill cancer cells. If licensed, with or without standard adjuvant treatment, pembrolizumab will offer an additional treatment option for patients with early-stage, operable NSCLC who currently have few well tolerated and effective therapies available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts